Patients with 0 or 1 CFH risk alleles and 1 or 2 ARMS2 risk alleles benefited from zinc-containing treatment compared with placebo , with an HR of 0.514 for zinc ( P = 0.012 ) and 0.569 for AF ( P = 0.0254 ) .